NovAccess Global Inc.

Equities

XSNX

US67001N1072

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 07:00:00 28/05/2024 pm IST			5-day change	1st Jan Change
0.014 ^USD	0.00%		0.00%	-30.35%

21/05	NovAccess Global Inc. Files Patent with Cedars-Sinai to Advance Its Brain Cancer Fighting Vaccine Platform	CI
15/05	NovAccess Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

Novaccess Global Inc. Reports Earnings Results for the Second Quarter Ended March 31, 2021

May 20, 2021 at 03:36 pm IST

NovAccess Global Inc. announced earnings results for the second quarter ended March 31, 2021. For the second quarter, the company announced operating loss was USD 281,320 compared to USD 139,203 a year ago. Net loss was USD 669,206 compared to net income of USD 38,543 a year ago. Basic loss per share from continuing operations was USD 0.05. For the half year, operating loss was USD 1.681 million compared to USD 260,809 a year ago. Net loss was USD 514,092 compared to USD 63,121 a year ago. Basic loss per share from continuing operations was USD 0.06.

Latest news about NovAccess Global Inc.

NovAccess Global Inc. Files Patent with Cedars-Sinai to Advance Its Brain Cancer Fighting Vaccine Platform	21/05	CI
NovAccess Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	15/05	CI
NovAccess Global Inc. announced that it has received $0.0265 million in funding from AJB Capital Investments LLC	29/04	CI
NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	28/02	CI
NovAccess Global Inc. announced that it has received $0.1 million in funding from AJB Capital Investments LLC	27/02	CI
NovAccess Global Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	09/02	CI
NovAccess Global Inc. Appoints Roscoe M. Moore, Jr. to Scientific Advisory Board	10/11	CI
NovAccess Global Inc. announced that it expects to receive $10.68 million in funding from Sumner Capital Pty Ltd.	01/23/01	CI
NovAccess Global Inc. announced that it expects to receive $0.055 million in funding	16/23/16	CI
NovAccess Global Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	12/23/12	CI
NovAccess Global Inc. Partners with BCN Biosciences to Expand Immunotherapy Platform	27/23/27	CI
NovAccess Global Inc. announced that it has received $0.055 million in funding from 1800 Diagonal Lending, LLC	20/23/20	CI
NovAccess Global Partners with CKN Ventures to Expand its New AI-driven Precision Medicine Division	16/23/16	CI
NovAccess Global Inc. Enters into a Letter Agreement with AJB Capital Investments, LLC	13/23/13	CI
NovAccess Global Inc. Launches Precision Medicine Division Using AI, Big Data and Predictive Technologies to Accelerate Personalised Healthcare Therapies	01/23/01	CI
NovAccess Global Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	16/23/16	CI
NovAccess Global Inc. announced that it has received $0.05425 million in funding from 1800 Diagonal Lending, LLC	28/23/28	CI
NovAccess Global Inc. announced that it expects to receive $0.05425 million in funding from 1800 Diagonal Lending, LLC	24/23/24	CI
NovAccess Global Inc. announced that it has received $0.07925 million in funding from 1800 Diagonal Lending, LLC	11/23/11	CI
NovAccess Global Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	15/23/15	CI
NovAccess Global Inc. announced that it has received $0.265 million in funding	09/23/09	CI
NovAccess Global Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	11/23/11	CI
NovAccess Global Inc. Auditor Raises 'Going Concern' Doubt	10/23/10	CI
NovAccess Global Inc. announced that it has received $0.055 million in funding from 1800 Diagonal Lending, LLC	07/22/07	CI
Novaccess Global Inc. Appoints Peter Weinstein to Scientific Advisory Board	11/22/11	CI

Chart NovAccess Global Inc.

Duration

Period

More charts

Company Profile

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patientâs own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patientâs tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
NOVACCESS GLOBAL INC.	-30.35%	624K
MODERNA, INC.	+54.05%	58.71B
IQVIA HOLDINGS INC.	-2.02%	41.31B
LONZA GROUP AG	+38.05%	39.2B
CELLTRION, INC.	-10.22%	27.4B
ICON PUBLIC LIMITED COMPANY	+13.42%	26.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.60%	18.98B
BIO-TECHNE CORPORATION	+2.89%	12.51B
UNITED THERAPEUTICS CORPORATION	+22.40%	11.94B
MEDPACE HOLDINGS, INC.	+27.49%	12.08B

Other Biotechnology & Medical Research